The Journal of Pediatrics
Volume 151, Issue 3 , Pages 228-230 , September 2007

Non! to Non-Steroidal Anti-Inflammatory Therapy for Inflammatory Lung Disease in Cystic Fibrosis (at Least at the Moment)

  • Andrew Bush, MB, BS (Hons), MA, MD, FRCP, FRCPCH

      Affiliations

    • Professor of Paediatric Respirology, Imperial School of Medicine at National Heart and Lung Institute, Honorary Consultant Paediatric Chest Physician, Royal Brompton Hospital, London, United Kingdom
    • Corresponding Author InformationReprint requests: Andrew Bush, Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
    • ,
  • Jane Davies, MB, ChB, MRCP, MRCPCH, MD

      Affiliations

    • Senior Lecturer in Gene Therapy, Imperial College, Honorary Consultant Paediatric Chest Physician, Royal Brompton Hospital, London, United Kingdom

References 

  1. Borza DB, Neilson EG, Hudson BG. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin Nephrol. 2003;23:522–531
  2. Konstan MW, Berger M. Infection and inflammation of the lungs in cystic fibrosis. In:  Davis PB editors. Cystic fibrosis. New York: Marcel Dekker; 1993;p. 219–276
  3. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985;2:686–688
  4. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr. 1995;126:515–523
  5. Dezateux C, Walters S, Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2000;2:CD001915
  6. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006;173:1356–1362
  7. Solomon MP, Wilson DC, Corey M, Kalnins D, Zielenski J, Tsui LC, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr. 2003;142:128–132
  8. Elkin SL, Vedi S, Bord S, Garrahan NJ, Hodson ME, Compston JE. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med. 2002;166:1470–1474
  9. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(Suppl 3):S225–S264
  10. Konstan M, Doring G, Lands LC. Results of a phase 11 clinical trial of B11L 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol. 2005;(Suppl 28):125–126
  11. Lands LC, Milner R, Cantin AM, Manson M, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007;151:249–254
  12. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;322:848–854
  13. Balfour-Lynn IM, Dezateux C. Corticosteroids and ibuprofen in cystic fibrosis. Thorax. 1999;54:657
  14. Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med. 1998;338:65–66
  15. Scott CS, Retsch-Bogart GZ, Henry MM. Renal failure and vestibular toxicity in an adolescent receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol. 2001;31:314–316
  16. Rinaldo JE, Pennock B. Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia. Am J Med Sci. 1986;291:29–38
  17. Merkus PJ, Tiddens HA, de Jongste JC. Annual lung function changes in young patients with chronic lung disease. Eur Respir J. 2002;19:886–891
  18. Merkus PJ, Govaere ES, Hop WC, Stam H, Tiddens HA, de Jongste JC. Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol. 2004;37:56–60
  19. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2006;61:155–157
  20. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res. 1997;41:161–165
  21. Alton EW, Davies JC, Geddes DM. Biomarkers for cystic fibrosis: are we progressing?. Am J Respir Crit Care Med. 2007;175:750–751
  22. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715–1721
  23. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med. 2005;172:831–836
  24. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163–2173
  25. Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med. 2005;171:1077–1082
  26. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60:215–218
  27. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91

PII: S0022-3476(07)00589-6

doi: 10.1016/j.jpeds.2007.06.019

The Journal of Pediatrics
Volume 151, Issue 3 , Pages 228-230 , September 2007

Article Tools